论文部分内容阅读
目的:研究ERCC1C8092A和C1900-7T、GSTP1al05G基因多态与中国晚期食管癌对顺铂(DDP)一线化疗的关系。方法:107例晚期食管癌患者以DDP和5-氟尿嘧啶(5-FU)方案化疗,最终98例患者按要求完成并进行临床疗效评价。检测上述基因位点多态性,分析基因多态性与缓解率、无进展生存时间之间的关系。结果:ERCC1-C8092AA/C或A/A型患者缓解率高于C/C型患者(51.7%vs29.0%,P=0.036),患者无进展生存时间长于C/C型患者(7.5个月vs4.5个月,P<0.0001);其他位点基因多态性与缓解率和无进展生存时间无显著相关性。结论:ERCC1C8092A基因多态性可能与晚期食管癌患者对DDP化疗疗效和无进展生存时间相关。
Objective: To investigate the relationship between the polymorphisms of ERCC1C8092A, C1900-7T and GSTP1al05G and the first-line chemotherapy of cisplatin (DDP) in advanced esophageal cancer in China. Methods: 107 patients with advanced esophageal cancer were treated with DDP and 5-fluorouracil (5-FU) regimen, and the final 98 patients were completed as required and the clinical efficacy was evaluated. Detection of the above-mentioned gene polymorphisms, analysis of gene polymorphism and remission rate, progression-free survival time relationship. Results: The patients with ERCC1-C8092AA / C or A / A had higher remission rates than those with C / C (51.7% vs 29.0%, P = 0.036) vs4.5 months, P <0.0001). There was no significant correlation between gene polymorphism and progression-free survival in other sites. Conclusion: The genetic polymorphisms of ERCC1C8092A may be related to the efficacy and progression-free survival of patients with advanced esophageal cancer.